Janus Henderson Group PLC Trims Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Janus Henderson Group PLC lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 160,689 shares of the medical research company’s stock after selling 4,492 shares during the period. Janus Henderson Group PLC’s holdings in IQVIA were worth $40,631,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. AdvisorNet Financial Inc boosted its stake in shares of IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares during the last quarter. Rise Advisors LLC acquired a new position in shares of IQVIA in the first quarter valued at approximately $31,000. Riverview Trust Co purchased a new position in shares of IQVIA during the first quarter valued at approximately $32,000. Covestor Ltd grew its stake in IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after acquiring an additional 48 shares during the period. Finally, Security National Bank purchased a new position in shares of IQVIA during the 4th quarter worth $41,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE:IQV traded up $3.19 on Wednesday, hitting $248.76. The company’s stock had a trading volume of 220,702 shares, compared to its average volume of 1,085,734. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock’s 50-day moving average is $220.70 and its two-hundred day moving average is $229.94. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a market capitalization of $45.35 billion, a price-to-earnings ratio of 33.55, a price-to-earnings-growth ratio of 2.24 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the business earned $2.22 earnings per share. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.21 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on IQV shares. Evercore ISI upped their price objective on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. The Goldman Sachs Group began coverage on shares of IQVIA in a research note on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. Truist Financial lifted their target price on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Morgan Stanley raised their price objective on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Finally, Robert W. Baird raised their price target on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $263.56.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.